Talphera Beheer

Beheer criteriumcontroles 3/4

De CEO Talphera is Vince Angotti, benoemd in Mar2017, heeft een ambtstermijn van 7.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.21M, bestaande uit 54.1% salaris en 45.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.71% van de aandelen van het bedrijf, ter waarde $ 84.70K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.5 jaar en 7.7 jaar.

Belangrijke informatie

Vince Angotti

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris	54.1%
Dienstverband CEO	7.7yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	7.5yrs
Gemiddelde ambtstermijn bestuur	7.7yrs

Recente managementupdates

Recent updates

AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well

Aug 18

AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm

Jul 27

FDA agrees with AcelRx to update promotional materials for Dsuvia

Jun 17

Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now

Jun 11

AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles

May 31

Analyse CEO-vergoeding

Hoe is Vince Angotti's beloning veranderd ten opzichte van Talphera's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$16m
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	US$1m	US$656k	-US$10m
Sep 30 2023	n/a	n/a	-US$11m
Jun 30 2023	n/a	n/a	-US$14m
Mar 31 2023	n/a	n/a	US$58m
Dec 31 2022	US$1m	US$637k	US$54m
Sep 30 2022	n/a	n/a	US$69m
Jun 30 2022	n/a	n/a	US$65m
Mar 31 2022	n/a	n/a	-US$31m
Dec 31 2021	US$2m	US$637k	-US$17m
Sep 30 2021	n/a	n/a	-US$36m
Jun 30 2021	n/a	n/a	-US$37m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$2m	US$637k	-US$40m
Sep 30 2020	n/a	n/a	-US$46m
Jun 30 2020	n/a	n/a	-US$50m
Mar 31 2020	n/a	n/a	-US$55m
Dec 31 2019	US$2m	US$618k	-US$53m
Sep 30 2019	n/a	n/a	-US$51m
Jun 30 2019	n/a	n/a	-US$51m
Mar 31 2019	n/a	n/a	-US$49m
Dec 31 2018	US$2m	US$600k	-US$47m
Sep 30 2018	n/a	n/a	-US$44m
Jun 30 2018	n/a	n/a	-US$45m
Mar 31 2018	n/a	n/a	-US$48m
Dec 31 2017	US$2m	US$493k	-US$52m

Compensatie versus markt: De totale vergoeding ($USD 1.21M ) Vince } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.78K ).

Compensatie versus inkomsten: De vergoeding van Vince is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Vince Angotti (56 yo)

7.7yrs

Tenure

US$1,211,994

Compensatie

Mr. Vincent J. Angotti, also known as Vince, has been the Chief Executive Officer of Talphera, Inc. (formerly known as AcelRx Pharmaceuticals, Inc.) since March 6, 2017. Mr. Angotti served as the Chief Exe...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Vincent Angotti	CEO & Director	7.7yrs	US$1.21m	0.71% $ 84.7k
Raffi Asadorian	Chief Financial Officer	7.3yrs	US$742.61k	0.082% $ 9.8k
Anil Dasu	Chief Engineering Officer	17.2yrs	US$686.35k	0.070% $ 8.4k
Shakil Aslam	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

7.5yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TLPH is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Vincent Angotti	CEO & Director	7.7yrs	US$1.21m	0.71% $ 84.7k
Mark Allen Wan	Independent Director	18.3yrs	US$69.79k	0.011% $ 1.3k
Stephen Hoffman	Independent Director	14.8yrs	US$47.29k	0.011% $ 1.3k
William Schmidt	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Adrian Adams	Independent Chairman	11.8yrs	US$104.79k	0.062% $ 7.5k
Marina Bozilenko	Independent Director	3.7yrs	US$62.29k	0.010% $ 1.3k
Jill Broadfoot	Independent Director	3yrs	US$62.29k	0.0075% $ 900.3
Eugene Viscusi	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Jonathan Schaffer	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Mary Southam	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Katsuto Shinohara	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Abhinav Jain	Independent Director	less than a year	geen gegevens	geen gegevens

7.7yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TLPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.7 jaar).

Talphera Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Talphera, Inc. Announces Management Changes

Talphera, Inc. Appoints Dr. Shakil Aslam as Chief Development Officer, Effective May 20, 2024

Talphera, Inc., Annual General Meeting, Jun 24, 2024

Talphera, Inc. Appoints Abhinav Jain to Serve as a Class II Director

AcelRx Pharmaceuticals, Inc., Annual General Meeting, Oct 10, 2023

AcelRx Pharmaceuticals, Inc. Announces Resignation of Mark G. Edwards as Board of Director

Recent updates

Talphera, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Talphera, Inc. Announces Management Changes

Talphera, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Talphera, Inc. Appoints Dr. Shakil Aslam as Chief Development Officer, Effective May 20, 2024

Talphera, Inc. to Report Q1, 2024 Results on May 14, 2024

Talphera, Inc., Annual General Meeting, Jun 24, 2024

Talphera, Inc. to Report Q4, 2023 Results on Mar 06, 2024

New major risk - Share price stability

Talphera, Inc. Appoints Abhinav Jain to Serve as a Class II Director

Talphera, Inc.(NasdaqGM:TLPH) dropped from NASDAQ Composite Index

Talphera Expects to Initiate the Registrational Study of Niyad

New major risk - Financial position

Consensus EPS estimates upgraded to US$1.16 loss, revenue downgraded

AcelRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

AcelRx Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

AcelRx Pharmaceuticals, Inc. Receives IDE Approval for Niyad and Advances to A Single Registration Study

AcelRx Pharmaceuticals, Inc., Annual General Meeting, Oct 10, 2023

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

AcelRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Shareholder dilution

Acelrx Pharmaceuticals Inc. Regains Compliance with Nasdaq Minimum Bid Price Rule

First quarter 2023 earnings released: EPS: US$0.006 (vs US$1.19 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.00

AcelRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022

AcelRx Pharmaceuticals Announces Reverse Stock Split to Regain Compliance

Consensus forecasts updated

Consensus forecasts updated

AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

AcelRx Pharmaceuticals, Inc. announced that it has received $0.3 million in funding from Lincoln Park Capital, LLC

Nasdaq Grants Additional time to AcelRx Pharmaceuticals to Regain Compliance

AcelRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

AcelRx Pharmaceuticals: Finally, Plan B

AcelRx Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates fall by 16%

AcelRx Pharmaceuticals, Inc. Provides Update on Reduced FDA REMS Requirements Related to DSUVIA

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Acelrx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (Sst) Compared to Standard Intravenous Opioids During Plastic Surgery Procedures Performed Under General Anesthesia

AcelRx Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$4.00

AcelRx Pharmaceuticals, Inc. Announces Summary of Results from Podium Presentation on DSUVIA, at the Aesthetic Meeting 2022

AcelRx Pharmaceuticals, Inc. Announces Publication of A Study Evaluating the Use of A Sufentanil Sublingual Tablet 30 Mcg for Management of Pain of Radiofrequency Microneedling of the Face or Abdomen

AcelRx Pharmaceuticals, Inc. Announces the Publication of Comparative Data Between Two Different Dialysis Circuit Anticoagulants in Pediatric Patients Undergoing Continuous Renal Replacement Therapy

Consensus forecasts updated

AcelRx Pharmaceuticals: Making Sense Of The Q4 Numbers

Full year 2021 earnings: EPS and revenues miss analyst expectations

AcelRx Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

AcelRx Pharmaceuticals, Inc. Announces Resignation of Mark G. Edwards as Board of Director

AcelRx Pharmaceuticals, Inc. Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet During Awake Plastic Surgery Procedures

AcelRx Pharmaceuticals: The Fog Is Getting Thicker

AcelRx Pharmaceuticals, Inc. (NasdaqGM:ACRX) completed the acquisition of Lowell Therapeutics, Inc.

AcelRx: Battered And Bruised But Ready For Recovery In 2022

AcelRx Pharmaceuticals, Inc. Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery

Consensus revenue estimates fall to US$4.66m

No longer forecast to breakeven

Price target decreased to US$4.25

Third quarter 2021 earnings released: US$0.07 loss per share (vs US$0.10 loss in 3Q 2020)

AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?

Second quarter 2021 earnings released: US$0.083 loss per share (vs US$0.082 loss in 2Q 2020)

AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm

AcelRx Pharmaceuticals, Inc.(NasdaqGM:ACRX) dropped from Russell 3000E Value Index

Rosen Law Firm Reminds Purchasers of the Securities of Acelrx Pharmaceuticals, Inc. Between March 17, 2020 and February 12, 2021

FDA agrees with AcelRx to update promotional materials for Dsuvia

Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now